DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: OXYCONTIN

Summary for Tradename: OXYCONTIN

Patents:8
Applicants:1
NDAs:1
Suppliers: see list6
2013 Sales:$2,534,909,000
drug
patent expirations by year for
 OXYCONTIN

Pharmacology for Tradename: OXYCONTIN

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

Clinical Trials for: OXYCONTIN

Pharmacokinetics Study of ALO-02 and OxyContin
Status: Completed Condition: Management of Moderate to Severe Pain

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone
Status: Completed Condition: Management of Moderate to Severe Pain

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone
Status: Completed Condition: Healthy

A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery
Status: Completed Condition: Postoperative Pain; Opioid Related Disorders

A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
Status: Recruiting Condition: Cancer

Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
Status: Completed Condition: Healthy

Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
Status: Completed Condition: Healthy

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Status: Completed Condition: Healthy

To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Status: Completed Condition: Healthy

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Status: Completed Condition: Healthy Volunteers

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272Apr 5, 2010RXNo6,488,963<disabled>Y<disabled>
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272Apr 5, 2010RXNo7,674,799<disabled>Y<disabled>
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272Apr 5, 2010RXNo7,674,800<disabled>Y<disabled>
Purdue Pharma Lp
OXYCONTIN
oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022272Apr 5, 2010RXNo7,683,072<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: OXYCONTIN

Drugname Dosage Strength RLD Submissiondate
oxycodone hydrochlorideExtended-release Tablet40 mgOxyContin (NDA 022272)10/4/2010
oxycodone hydrochlorideExtended-release Tablet30 mg, 60 mg and 80 mgOxyContin (NDA 022272)10/18/2010
oxycodone hydrochlorideExtended-release Tablet20 mgOxyContin (NDA 022272)10/29/2010
oxycodone hydrochlorideExtended-release Tablet15 mgOxyContin (NDA 022272)10/28/2010
oxycodone hydrochlorideExtended-release Tablet10 mgOxyContin (NDA 022272)10/25/2010
oxycodone hydrochlorideExtended-release Tablets15 mgOxycontin2/15/2007
oxycodone hydrochlorideExtended-release Tablets30 mg and 60 mgOxycontin1/3/2007

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc